Organization
Adagene
8 clinical trials
Clinical trial
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-30
Clinical trial
A Phase 1b, Open-Label, Dose Escalation Study of ADG116 in Combination With Pembrolizumab (Anti-PD-1 Antibody) in Patients With Advanced/Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-08-01
Clinical trial
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined With Toripalimab (Anti-PD-1 Antibody), ADG116 Combined With ADG106 (Anti-CD137 Antibody) in Patients With Advanced/Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination With PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2023-02-09
Clinical trial
A Phase Ⅰ Study of ADG106 Administered in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2021-11-01
Clinical trial
A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2022-01-24
Clinical trial
A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-04-01